Pharma: Clinic roundup

Astrazeneca plc, of London, reported phase III data showing that the combination of saxagliptin/dapagliflozin, as a dual add-on therapy in adults with type 2 diabetes who were inadequately controlled on metformin, resulted in statistically significant reductions in HbA1c with the combination vs. either agent alone.